News on mass spectrometry technology and applications in genetics, genomics, and molecular diagnostics.
The companies will combine their respective technologies to develop mass spectrometry-based proteomics assays for adverse pregnancy outcomes.
As the circle of doctors ordering drug testing expands, labs find themselves more involved in advisory and interpretive roles that go beyond running assays.
The mass spec-based assay can detect viral proteins eight days after the onset of symptoms, compared to four to five days with PCR tests, its developers said.
The funding will be used to run a study of breath-based biomarkers and measures of small airway function to enable the definitive diagnosis of asthma.
The firm has launched a 2,300-subject prospective study evaluating the test, which measures exosome proteins to assess a woman's risk of preterm delivery.
